{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:03:01Z","timestamp":1792605781231,"version":"4.5.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiac amyloidosis is a rare, debilitating, and usually fatal disease increasingly recognized in clinical practice despite patients presenting with non-specific symptoms of cardiomyopathy. The current standard of care (SoC) focuses on preventing further amyloid formation and deposition, either with anti-plasma cell dyscrasia (anti-PCD) therapies in light-chain (AL) amyloidosis or stabilizers of transthyretin (TTR) in transthyretin amyloidosis (ATTR). The SoC is supplemented by therapies to treat the complications arising from organ dysfunction; for example, heart failure, arrhythmia, and proteinuria. Advancements in treatments have improved patient survival, especially for those whose disease is detected and for whom treatment is initiated at an early stage. However, there still are many unmet medical needs, particularly for patients with severe disease for whom morbidity and mortality remain high. There currently are no approved treatments to reverse amyloid infiltration and deplete the amyloid fibrils already deposited in organs, which can continue to cause progressive dysfunction. Anti-fibril therapies aimed at removing the deposited fibrils are being investigated for safety and efficacy in improving outcomes for patients with severe disease. However, there is no clinical evidence yet that removing deposited amyloid fibrils will improve organ function, thereby improving quality of life or extending life. Nevertheless, anti-fibril therapies are actively being investigated in clinical trials to evaluate their ability to complement and synergize with current SoC.<\/jats:p>","DOI":"10.3389\/fcvm.2022.1073503","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:06:53Z","timestamp":1671523613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"C. Cristina","family":"Quarta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Catini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Simoneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: Update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opin Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11864-020-00738-8","article-title":"Advances in the treatment of cardiac amyloidosis","volume":"21","author":"Macedo","year":"2020","journal-title":"Curr Treat Options Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imag."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","article-title":"Cardiac amyloidosis: An underdiagnosed\/underappreciated disease","volume":"67","author":"Manolis","year":"2019","journal-title":"Eur J Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/ejh.13472","article-title":"Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis","volume":"105","author":"Schulman","year":"2020","journal-title":"Eur J Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101366","DOI":"10.1016\/j.cpcardiol.2022.101366","article-title":"A review of cardiac amyloidosis: presentation, diagnosis, and treatment","volume":"2022","author":"Pour-Ghaz","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41375-020-0802-4","article-title":"Systemic amyloidosis: Moving into the spotlight","volume":"34","author":"Cohen","year":"2020","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2217\/cer-2021-0071","article-title":"Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"J Comp Eff Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","article-title":"Amyloidosis in heart failure","volume":"16","author":"Ihne","year":"2019","journal-title":"Curr Heart Fail Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40119-021-00222-w","article-title":"Multidisciplinary approaches for transthyretin amyloidosis","volume":"10","author":"Koike","year":"2021","journal-title":"Cardiol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/JBM.S183857","article-title":"Treatment options for relapsed\/refractory systemic light-chain (AL) amyloidosis: current perspectives","volume":"10","author":"Sarosiek","year":"2019","journal-title":"J Blood Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","article-title":"Perspectives in treatment of AL amyloidosis","volume":"140","author":"Wechalekar","year":"2008","journal-title":"Br J Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ajh.23400","article-title":"Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment","volume":"88","author":"Gertz","year":"2013","journal-title":"Am J Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage iiib) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"2022","author":"Wechalekar","year":"2022","journal-title":"Amyloid."},{"key":"B28","unstructured":"PennsylvaniaNational Comprehensive Cancer NetworkSystemic Light Chain Amyloidosis: NCCN Evidence Blocks\u2122 v2: NCCN.org.2021"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/bloodadvances.2020002219","article-title":"Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis","volume":"4","author":"Basset","year":"2020","journal-title":"Blood Adv."},{"key":"B30","article-title":"Alkylating agents","volume-title":"Holland-Frei Cancer Medicine Hamilton.","author":"Colvin","year":"2003"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.5772\/63467","article-title":"Proteasome inhibitors to treat AL amyloidosis","volume-title":"Exploring New Findings on Amyloidosis.","author":"Driscoll","year":"2016"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"26922","DOI":"10.18632\/oncotarget.4616","article-title":"Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma","volume":"6","author":"Kervo\u00eblen","year":"2015","journal-title":"Oncotarget."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0257189","DOI":"10.1371\/journal.pone.0257189","article-title":"Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement","volume":"16","author":"B\u00e9zard","year":"2021","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2017.02.004","article-title":"Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis","volume":"76","author":"Le Bras","year":"2017","journal-title":"Eur J Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.16898","article-title":"Challenges in the management of patients with systemic light chain (AL) amyloidosis during the covid-19 pandemic","volume":"190","author":"Kastritis","year":"2020","journal-title":"Br J Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e30263","DOI":"10.7759\/cureus.30263","article-title":"Light chain amyloidosis presenting as a septic shock: a case report and review of literature","volume":"14","author":"Bazzi","year":"2022","journal-title":"Cureus."},{"key":"B40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"Cd38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus cybord for patients with newly diagnosed AL amyloidosis: safety run-in results of andromeda","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/10428194.2018.1485914","article-title":"Daratumumab for the treatment of AL amyloidosis","volume":"60","author":"Sidiqi","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1111\/imj.15926","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis","volume":"52","author":"Brennan","year":"2022","journal-title":"Intern Med J."},{"key":"B45","first-page":"430","article-title":"Treatment tolerability in patients with immunoglobulin light-chain amyloidosis","volume":"11","author":"Rizio","year":"2018","journal-title":"Am Health Drug Benefits."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.clinthera.2018.12.003","article-title":"Cyclophosphamide + thalidomide + dexamethasone vs. melphalan + dexamethasone for the treatment of amyloid light-chain amyloidosis with kidney involvement: a retrospective study in Chinese patients","volume":"41","author":"Liu","year":"2019","journal-title":"Clin Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Prog."},{"key":"B48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000506760","article-title":"Supportive care in AL amyloidosis","volume":"143","author":"Cibeira","year":"2020","journal-title":"Acta Haematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","article-title":"Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study","volume":"114","author":"Reece","year":"2009","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/13506129.2020.1767566","article-title":"Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients","volume":"27","author":"Milani","year":"2020","journal-title":"Amyloid."},{"key":"B51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bjh.16436","article-title":"Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits","volume":"189","author":"Popkova","year":"2020","journal-title":"Br J Haematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: An update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail."},{"key":"B54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid."},{"key":"B55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cjca.2019.12.033","article-title":"Amyloidosis as a systemic disease in context","volume":"36","author":"Cuddy","year":"2020","journal-title":"Can J Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","article-title":"Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis","volume":"27","author":"Morfino","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int J Biomed Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imag."},{"key":"B67","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"2022","author":"Adams","year":"2022","journal-title":"Amyloid."},{"key":"B69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 neuro-ttransform study of antisense oligonucleotide AKCEA-TTR-LRx (ion-682884-cs3) in hereditary transthyretin-mediated amyloid polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FJC.0000000000001004","article-title":"A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis","volume":"77","author":"Benbrahim","year":"2021","journal-title":"J Cardiovasc Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","article-title":"Transthyretin cardiac amyloidoses in older north americans","volume":"60","author":"Dharmarajan","year":"2012","journal-title":"J Am Geriatr Soc."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"25080","DOI":"10.1038\/srep27679","article-title":"Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses","volume":"6","author":"Galant","year":"2016","journal-title":"Sci Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"Ag10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated v122i transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin amyloid cardiomyopathy-current and future therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann Pharmacother."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(22)01218-9","article-title":"Long-term safety and tolerability of acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy: updated analysis from an ongoing phase 2 open-label extension study","author":"Masri","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-o-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid."},{"key":"B81","first-page":"S107","article-title":"Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges","volume":"23","author":"Gertz","year":"2017","journal-title":"Am J Manag Care."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1021\/bi0616605","article-title":"Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains","volume":"46","author":"O'Nuallain","year":"2007","journal-title":"Biochemistry."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS ONE."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2021-151908","article-title":"Pre-clinical characterization of a novel fusion protein (AT-03), with pan-amyloid binding and removal","volume":"138","author":"Sirac","year":"2021","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/hematology.2021000305","article-title":"AL amyloidosis: untangling new therapies","volume":"2021","author":"Bal","year":"2021","journal-title":"Hematology."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the phase 3 vital study of neod001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients","author":"Gertz","year":"2019","journal-title":"Blood."},{"key":"B88","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.1002\/ajh.24563","article-title":"Organ response in patients with AL amyloidosis treated with neod001, an amyloid-directed monoclonal antibody","volume":"91","author":"Gertz","year":"2016","journal-title":"Am J Hematol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076","article-title":"Birtamimab in patients with Mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study","author":"Gertz","year":"2022","journal-title":"J Clin Oncol."},{"key":"B90","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1f4","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1089\/108497803322702824","article-title":"Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies","volume":"18","author":"Solomon","year":"2003","journal-title":"Cancer Biother Radiopharm."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","article-title":"Radioimmunodetection of amyloid deposits in patients with AL amyloidosis","volume":"116","author":"Wall","year":"2010","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1f4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid."},{"key":"B94","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1182\/blood.V128.22.643.643","article-title":"Analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1f4 in patients with AL amyloidosis","volume":"128","author":"Edwards","year":"2016","journal-title":"Blood."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1f4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152488","article-title":"Cardiac Amyloid Reaching for Extended Survival (CARES): study design of two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis","author":"Wechalekar","year":"2021","journal-title":"Blood."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1073503\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T04:21:23Z","timestamp":1701577283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1073503\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":97,"alternative-id":["10.3389\/fcvm.2022.1073503"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1073503","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"article-number":"1073503"}}